Panbela announces first patient enrolled in dose escalation study of CPP-1X-S

Panbela Therapeutics announced the first patient enrolled in a Phase I dose escalation study to evaluate CPP-1X-S in STK11 mutant non-small cell lung cancer, NSCLC. The initial goal of the Phase I trial will be to determine the maximum tolerated dose of eflornithine in combination with the immune checkpoint inhibitor Keytruda, while evaluating efficacy and then moving into a Phase II efficacy trial. Data from the Phase I trial is expected by mid-2025, with a look to start the Phase II trial in 2024.